2022
Using machine learning to predict heavy drinking during outpatient alcohol treatment
Roberts W, Zhao Y, Verplaetse T, Moore KE, Peltier MR, Burke C, Zakiniaeiz Y, McKee S. Using machine learning to predict heavy drinking during outpatient alcohol treatment. Alcohol Clinical And Experimental Research 2022, 46: 657-666. PMID: 35420710, PMCID: PMC9180421, DOI: 10.1111/acer.14802.Peer-Reviewed Original ResearchConceptsAlcohol use disorderHeavy drinkingTreatment outcomesInvasive assessment methodsOutpatient AUD treatmentLast monthOutpatient alcohol treatmentMultisite clinical trialAccurate clinical predictionsHeavy alcohol useSex differencesBi-weekly sessionsAlcohol treatment outcomesPatient characteristicsClinical outcomesClinical trialsClinical dataStratified analysisEffective treatmentPsychiatric disordersUse disordersAUD treatmentSubstantial sex differencesAlcohol treatmentFirst month
2020
A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
Roberts W, Verplaetse TL, Ramchandani VA, McKee SA. A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers? Alcohol Clinical And Experimental Research 2020, 45: 15-24. PMID: 33190310, PMCID: PMC7855436, DOI: 10.1111/acer.14514.Peer-Reviewed Original ResearchConceptsHuman laboratory studiesTreatment seekersNontreatment seekersExpensive clinical trialsPatient populationAlcohol administrationClinical trialsMedication effectsClinical conditionsMedication developmentMedicationsHeavy drinkersMedication experimentsLaboratory screeningClinical realityAdministration guidelinesScreening researchDevelopment pipelineLaboratory studiesRiskGuidelinesParticipantsPharmacotherapyPopulationEthical guidelinesAssociations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study
Verplaetse TL, Peltier MR, Roberts W, Moore KE, Pittman BP, McKee SA. Associations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study. Nicotine & Tobacco Research 2020, 22: 1316-1321. PMID: 32152625, PMCID: PMC7364844, DOI: 10.1093/ntr/ntaa022.Peer-Reviewed Original ResearchConceptsNicotine metabolite ratioFaster nicotine metabolismHigher nicotine metabolite ratioE-cigarette useCigarette smoking statusSlower nicotine metabolismNicotine metabolismE-cigarettesSmoking statusCigarette smokingMetabolite ratiosE-cigarette use statusPopulation-based studyLongitudinal cohort studyWave 1Cigarette smoking behaviorCohort studyClinical trialsTobacco usePATH studyHealth StudySmoking behaviorEarly interventionUS populationCombustible cigarettes
2019
Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder
Verplaetse TL, Ralevski E, Roberts W, Gueorguieva R, McKee SA, Petrakis IL. Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. Alcohol Clinical And Experimental Research 2019, 43: 741-746. PMID: 30698839, PMCID: PMC6443463, DOI: 10.1111/acer.13969.Peer-Reviewed Original ResearchConceptsAlcohol use disorderPosttraumatic stress disorderPlacebo-treated individualsTotal CAPS scoresClinical trialsCAPS scoresPrazosin treatmentComorbid populationPTSD symptomsUse disordersClinician-Administered PTSD Scale scoresDouble-blind clinical trialStress disorderComorbid alcohol use disorderPrazosin-treated groupSymptoms of PTSDRecent clinical trialsComorbid alcohol dependenceCourse of treatmentΑ1-adrenergic antagonistPosttraumatic stress disorder (PTSD) symptomsOngoing symptomsSleep disturbancesMedication effectsNoradrenergic system
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differences